SEC Form 4 · accession 0001144204-15-021900
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Luciano Adorini
Officer — Chief Scientific Officer
Period of report
Apr 6, 2015
Accepted (ET)
Apr 8, 2015 · 9:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 6, 2015 | M | 4,000 | $8.6667 | A | 14,060 | D | |
| Common Stock | Apr 6, 2015 | S | 1,000 | $266.18 | D | 13,060 | D | |
| Common Stock | Apr 6, 2015 | S | 1,000 | $269.11 | D | 12,060 | D | |
| Common StockF3 | Apr 6, 2015 | S | 2,000 | $271.64 | D | 10,060 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2 | $8.6667 | Apr 6, 2015 | M | 4,000 | D | — | Sep 6, 2020 | Common Stock | 4,000 | 4,000 | D |
Explanation of responses
- F1The reported transaction was made pursuant to a 10(b)5-1 plan adopted by the reporting person on March 9, 2015.
- F2All the shares underlying this option have fully vested.
- F3This transaction was executed in multiple trades at prices ranging from $271.27 to $272.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.